Assisted Reproductive Technology Market Report 2026

The assisted reproductive technology market size has grown strongly in recent years. It will grow from $37.06 billion in 2025 to $40.46 billion in 2026 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to rising infertility prevalence, increasing maternal age trends, expansion of fertility clinics, availability of assisted reproductive procedures, growing social acceptance of art treatments.

The assisted reproductive technology market size is expected to see strong growth in the next few years. It will grow to $56.96 billion in 2030 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to increasing adoption of precision fertility diagnostics, rising investments in fertility treatment infrastructure, expansion of genetic testing applications, growing demand for minimally invasive procedures, increasing healthcare spending on reproductive health. Major trends in the forecast period include increasing adoption of advanced embryo screening techniques, rising use of frozen embryo and egg banking, growing demand for personalized fertility treatments, expansion of genetic testing in art procedures, enhanced focus on treatment success rates.

The increasing prevalence of infertility cases is anticipated to boost the assisted reproductive technology market in the coming years. Infertility is described as the inability to achieve pregnancy after a year of regular, unprotected sexual intercourse. It affects both men and women and is generally identified by the failure to conceive. Assisted reproductive technology (ART) is used to treat infertility. This includes fertility treatments that involve both a woman's egg and a man's sperm. For example, in April 2023, according to the World Health Organization (WHO), a Switzerland-based international public health organization, millions of people of reproductive age worldwide face infertility, which also impacts their families and communities. Globally, it is estimated that 1 in 6 adults, or roughly 17.5% of the adult population, experience infertility. Consequently, the growing number of infertility cases fuels the expansion of the assisted reproductive technology market.

Major companies in the assisted reproductive technology market are concentrating on developing advanced solutions, such as next-generation sequencing (NGS)-based testing kits, to enhance chromosomal analysis, improve embryo selection, and increase the success rates of fertility treatments. NGS-based preimplantation genetic testing involves research-use technologies that allow comprehensive evaluation of chromosomal abnormalities in embryos, supporting informed decision-making during IVF and ICSI procedures. For example, in July 2023, Thermo Fisher Scientific Inc., a US-based biotechnology company, introduced two next-generation sequencing-based products, the Ion ReproSeq PGT-A Kit and the Ion AmpliSeq Polyploidy Kit, to facilitate preimplantation genetic testing for aneuploidy (PGT-A). Designed for reproductive health laboratories, these assays are the first research-use products of their kind and are compatible with the Ion Torrent Genexus Integrated Sequencer, enabling a streamlined workflow from sample processing to aneuploidy analysis. PGT-A testing identifies chromosomal abnormalities in embryo samples, and these new solutions aim to advance scientific understanding, improve pregnancy success rates, and support healthier outcomes for future generations. The Genexus platform further simplifies the research process through integrated templating, sequencing, and data analysis, while the Ion AmpliSeq Polyploidy Panel kit provides enhanced quality control features to detect contamination, prevent sample mix-ups, and identify triploidy in embryos, reinforcing technological advancement within the assisted reproductive technology market.

In November 2023, CooperCompanies, a US-based medical device company, acquired Cook Medical's Reproductive Health business in a deal valued at $300 million. The acquired products complement CooperSurgical’s existing medical device portfolio and strengthen the company's position as a leading global provider in fertility and women’s health. Cook Medical is a US-based provider of assisted reproductive technology.

Major companies operating in the assisted reproductive technology market are Cooper Surgical Inc., Ferring Pharmaceuticals Ltd., Hamilton Thorne Ltd., Merck KGaA, Genea Limited, California Cryobank, European Sperm Bank, OvaScience Inc., Bloom IVF Centre, Vitrolife AB, FUJIFILM Irvine Scientific Inc., Nidacon International AB, Monash IVF Group Ltd., Cook Medical, INVO Bioscience Inc., Thermo Fisher Scientific Inc., Anecova Sa, Carolinas Fertility Institute, Microm Ltd., Inception Sciences Inc., Progyny Inc., Oxford Gene Technology IP Ltd., IVI-RMA Global, Boston IVF, CARE Fertility Group, Virtus Health, Reproductive Medicine Associates of New York, Shady Grove Fertility, CCRM Fertility, New Hope Fertility Center, Houston Fertility Institute, Pacific Fertility Center, RMA of New Jersey, Sher Fertility Institute, IVF Florida, ORM Fertility, HRC Fertility, Arizona Center for Reproductive Endocrinology & Infertility, San Diego Fertility Center, Fertility Centers of Illinois.

Europe was the largest region in the assisted reproductive technology market in 2025. North America was the second-largest region in assisted reproductive technology market. The regions covered in the assisted reproductive technology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the assisted reproductive technology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the assisted reproductive technology market by increasing costs of imported laboratory equipment, genetic testing kits, cryopreservation systems, consumables, and specialized medical devices. Fertility clinics and hospitals in North America and Europe are most affected due to reliance on imported laboratory technologies, while Asia-Pacific faces cost pressures on equipment exports. These tariffs are raising treatment costs and influencing patient affordability. However, they are also encouraging domestic manufacturing of fertility equipment, regional laboratory setup, and innovation in cost-efficient reproductive technologies.

The assisted reproductive technology market research report is one of a series of new reports that provides assisted reproductive technology market statistics, including assisted reproductive technology industry global market size, regional shares, competitors with a assisted reproductive technology market share, detailed assisted reproductive technology market segments, market trends and opportunities, and any further data you may need to thrive in the assisted reproductive technology industry. This assisted reproductive technology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Assisted reproductive technology involves the surgical retrieval of eggs from a woman’s ovaries, which are then combined with a man’s sperm in a laboratory to form embryos. These embryos are subsequently transferred back into the woman’s body. ART may utilize donor eggs, donor sperm, or previously cryopreserved embryos. Assisted reproductive technology (ART) is applied in the treatment of infertility related to eggs or embryos.

The primary forms of assisted reproductive technology include in-vitro fertilization (IVF), artificial insemination (AI-IUI), frozen embryo replacement (FER), and others. In-vitro fertilization (IVF) is a complex procedure that involves retrieving eggs and fertilizing them with sperm in a laboratory to create embryos. These embryos are then transferred into the reproductive organs of women. The various procedure types include fresh non-donor, fresh donor, frozen donor, frozen non-donor, embryo or egg banking, and they are utilized in hospitals, fertility clinics, and other settings.

The assisted reproductive technology market includes revenues earned by entities by gamete intrafallopian transfer (GIFT), zygote intrafallopian transfer (ZIFT), and frozen embryo transfer (FET). The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.